ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2022 and some content may be unavailable. To unlock all content for 2022, please visit the archives.

Abstract: TH-PO996

POWERED Study: Prophylaxis With Metformin to Prevent Post-Transplant Diabetes Mellitus

Session Information

Category: Transplantation

  • 2002 Transplantation: Clinical


  • Allan, Michelle Elizabeth, Barts Health NHS Trust, London, London, United Kingdom
  • Chowdhury, Tahseen Ahmad, Barts Health NHS Trust, London, London, United Kingdom
  • Fan, Stanley, Barts Health NHS Trust, London, London, United Kingdom
  • Yaqoob, Muhammad Magdi, Barts Health NHS Trust, London, London, United Kingdom
  • Mccafferty, Kieran, Barts Health NHS Trust, London, London, United Kingdom

Advances in immunosuppression have improved kidney transplant outcomes. However, calcineurin inhibitors and steroids, and other transplant-specific and general diabetogenic risk factors, contribute to the development of post-transplant diabetes mellitus (PTDM). PTDM is associated with increased cardiovascular morbidity and mortality, graft loss and infection. Despite its clinical relevance, there has been a historic lack of diagnostic criteria or clear management strategies. Rather than treating patients who have already developed PTDM, new trials are focusing on prevention.


We present the results of a single-centre prospective randomised placebo-controlled trial comparing metformin 500mg OD vs placebo in kidney transplant recipients in the first 3 months post-transplant. 60 patients who passed screening within 10 days of transplant, including eGFR >/=30ml/min and 2hr oral glucose tolerance test (OGTT) <11.1 mmol/L, were randomised to either metformin (n=30) or placebo (n=30). They returned at 3, 6 and 12 months post-transplant for fasting bloods, including OGTT.

The primary endpoint was a diagnosis of PTDM, defined by a positive OGTT. Secondary endpoints included the effect on HbA1c, HOMA-IR, impaired glucose tolerance or elevated fasting plasma glucose, renal function, graft/patient survival and safety.


The groups were well-matched for baseline demographics including age, ethnicity, BMI, cause of ESRF, co-morbidities, immunological risk and induction. There was no significant difference in PTDM development survival curves by either OGTT or composite outcome (OGTT, IGT, FPG, HbA1c, Rx) log-rank p0.53 and p0.41, respectively. There was no difference in renal function, HOMA-IR or in safety signal.


Metformin was not associated with a reduction in the diagnosis of PTDM at this dose and in this study which was significantly impacted by the COVID-19 pandemic, especially with regards to missing data during follow-up. However, there is no contraindication to further studies including larger doses of metformin or patients with positive OGTT at baseline.

Figure 1: time to PTDM diagnosis


  • Clinical Revenue Support